Semret Makeda, Abebe Workeabeba, Kong Ling Yuan, Alemayehu Tinsae, Beyene Temesgen, Libman Michael D, Amogne Wondwossen, Johannsen Øystein Haarklau, Gebretekle Gebremedhin B, Seifu Daniel, Yansouni Cedric P
Department of Medicine and JD MacLean Centre for Tropical Diseases, McGill University Health Centre, Montreal, Quebec, Canada.
School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia.
JAC Antimicrob Resist. 2020 Jul 7;2(3):dlaa039. doi: 10.1093/jacamr/dlaa039. eCollection 2020 Sep.
Hospital-associated infection (HAI) and antimicrobial resistance (AMR) are major health threats in low- and middle-income countries (LMICs). Because diagnostic capacity is lacking throughout most of Africa, patients are commonly managed with prolonged empirical antibiotic therapy. Our goal was to assess mortality in relation to HAI and empirical therapy in Ethiopia's largest referral hospital.
Cohort study of patients with suspected HAI at Tikur Anbessa Specialized Hospital from October 2016 to October 2018. Blood culture testing was performed on an automated platform. Primary outcomes were proportion of patients with bloodstream infection (BSI), antibiotic resistance patterns and 14 day mortality. We also assessed days of therapy (DOT) pre- and post-blood culture testing.
Of 978 enrolled patients, 777 had blood culture testing; 237 (30%) had a BSI. Enterobacteriaceae were isolated in 49%; 81% of these were cephalosporin resistant and 23% were also carbapenem resistant. Mortality at 14 days was 31% and 21% in those with and without BSI, respectively. Ceftriaxone resistance was strongly correlated with mortality. Patients with BSI had longer DOT pre-blood culture testing compared with those without BSI (median DOT 12 versus 3 days, respectively, <0.0001). After testing, DOT were comparable between the two groups (20 versus 18 days, respectively).
BSI are frequent and fatal among patients with suspected HAI in Ethiopia. Highly resistant blood isolates are alarmingly common. This study provides evidence that investing in systematic blood culture testing in LMICs identifies patients at highest risk of death and that empirical management is frequently inappropriate. Major investments in laboratory development are critical to achieve better outcomes.
医院获得性感染(HAI)和抗菌药物耐药性(AMR)是低收入和中等收入国家(LMICs)面临的主要健康威胁。由于非洲大部分地区缺乏诊断能力,患者通常接受长时间的经验性抗生素治疗。我们的目标是评估埃塞俄比亚最大的转诊医院中与HAI和经验性治疗相关的死亡率。
对2016年10月至2018年10月在提库尔·安贝萨专科医院疑似HAI的患者进行队列研究。在自动化平台上进行血培养检测。主要结局是血流感染(BSI)患者的比例、抗生素耐药模式和14天死亡率。我们还评估了血培养检测前后的治疗天数(DOT)。
在978名登记患者中,777名进行了血培养检测;237名(30%)发生了BSI。分离出的肠杆菌科细菌占49%;其中81%对头孢菌素耐药,23%对碳青霉烯类也耐药。有BSI和无BSI的患者14天死亡率分别为31%和21%。头孢曲松耐药与死亡率密切相关。与无BSI的患者相比,有BSI的患者在血培养检测前的DOT更长(中位数DOT分别为12天和3天,<0.0001)。检测后,两组的DOT相当(分别为20天和18天)。
在埃塞俄比亚,疑似HAI患者中BSI很常见且致命。高度耐药的血液分离株惊人地普遍。这项研究提供了证据,即在LMICs中投资于系统性血培养检测可识别出死亡风险最高的患者,且经验性治疗往往不合适。对实验室发展进行重大投资对于取得更好的结果至关重要。